Literature DB >> 1954007

EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.

.   

Abstract

Mesh:

Substances:

Year:  1991        PMID: 1954007

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


× No keyword cloud information.
  5 in total

1.  Acceptability of continuous cell lines for the production of biologicals.

Authors:  J Löwer
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

2.  Evaluation of the new serum-free medium (MDSS2) for the production of different biologicals: use of various cell lines.

Authors:  O W Merten; J V Kierulff; N Castignolles; P Perrin
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

Review 3.  C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option.

Authors:  H J Longhurst; S Carr; K Khair
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

Review 4.  Validation of biopharmaceutical purification processes for virus clearance evaluation.

Authors:  Allan Darling
Journal:  Mol Biotechnol       Date:  2002-05       Impact factor: 2.695

Review 5.  Pathogen safety of plasma-derived products - Haemate P/Humate-P.

Authors:  A Gröner
Journal:  Haemophilia       Date:  2008-11       Impact factor: 4.287

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.